Kleine Moleküle & Peptide

DOTA-[Pro1,Tyr4]bombesin (1-14)

Precursor for radiolabelled DOTA-[Pro1,Tyr4]bombesin (1-14)

Bombesin, 1-[1-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-; MP2346; DOTA-[P1, Y4]BBN(1-14); CA index name: Bombesin, 1-[1-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-

Sequence: DOTA-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂; DOTA = [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl; Supplied as acetate salt

Qualität

Research Chemical

Eigenschaften

Molare Masse 2042.28

CAS RN [593287-40-2] (net peptide)

Reinheit ≥ 95 %

  • Colorless to off-white freeze-dried solid

Zertifikate

CoA: appearance, MS (identity), HPLC (purity)

Literatur

Biddlecombe G.B. et al. Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice Using ⁶⁴Cu- and ⁸⁶Y-DOTA-[Pro1,Tyr4]-Bombesin(1–14). Bioconjug Chem. 2007, 18, 724–30.

Breeman W.A. et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999, 81, 658–65.

Breeman W.A. et al. Preclinical comparison of ¹¹¹In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002, 43, 1650–56.

Zur Anfrage hinzufügen

ProduktnummerFüllmengeAnzahl
Produktnummer: 9715Füllmenge: 1 mg
Produktnummer: 9715Füllmenge: 10 mg
Produktnummer: 9715
Produkt hinzugefügt